BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $1,001.00 price target on Eli Lilly (NYSE: LLY).

The analyst commented, "Lilly's first oncology analyst event in recent memory shed light on a growing part of the business, one that has reinvented itself from a 2019 reset into an organization that appears ready to deliver across readouts in the next five years. Although its incretin portfolio is what should drive exceptional growth in the near term, financial strength should drive expansion across a number of therapeutic areas. Ultimately, we came away from today's event pleased with the level of thought and consideration that has gone into the diversification of Lilly's business."

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $820.34 yesterday.

You May Also Be Interested In

• Winnebago Industries (WGO) PT Lowered at BMO Capital 'as Retail/Shipment Softness Continues'
• Eli Lilly plans European weight-loss pill launch by early 2027
• Acuity Brands (AYI) PT Raised to $465 at Oppenheimer